Diligence memo · auto-generated · as of July 2, 2026
Kalytera Therapeutics, Inc.
Kalytera Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Kalytera Therapeutics, Inc. operates in Pharma, based in SAN RAFAEL.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kalytera Therapeutics, Inc. has raised $2.2M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $760K on 2019-09-13.
Most recent recorded round closed around 2019-09-13.
Valuation (modeled)modeled
Provath models Kalytera Therapeutics, Inc. at approximately $36M (range $426K–$408M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.67× the median modeled value of Pre-Seed Pharma companies in 2019–2021 (20 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 6.8 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 5.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 45% of Pharma peers (310 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Jupiter Therapeutics, Inc., Tavros Therapeutics, Inc., Veterinary Radiation Oncology of the Chesapeake, LLC, Chamishi Therapeutics, Inc., Ikaika Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.